Miracle drug creates a new hope for millions of kidney patients around the world.
This incredible 2-a-day pill may represent the greatest breakthrough in the history of
kidney disease.
Hello, how are your kidneys doing?
This is Katherine.
Welcome to 00Kidney!
Don't forget to subscribe and turn on notifications!
In decades of studies, researchers have always focused on reducing the speed of the progression
of kidney disease instead of actually trying to stop this devastating illness.
Now, for the first time, things are changing.
Actually undergoing human trials in Australia, the miracle drug could be able to change the
lives of 29 million people.
Researchers are taking a whole new approach, focusing on fighting the triggering factors
of scarring and inflammation in the kidney instead of just trying to slow down the progression
of the disease.
This may be a game changer.
The drug, called GKT831 is in phase-II trials.
This means that the drug is being tested on actual patients and not on healthy people
or animals.
But how does it work?
GKT831 is a NOX-inhibitor, it blocks a pathway through which NOX1 and NOX4 enzymes cause
damages to the kidneys.
The use of NOX-inhibitor to fight the enzymes responsible of kidney damages is not entirely
new.
But the results have never been this positive before.
The new drug has already shown its potential during the tests on mice.
I want to explain why I think this drug will be a life saver for many.
This is the first time the field is taking a true step back, not just focusing on palliatives
and life support but re-examining where they are in regard to what they know.
Yes, this time scientists are looking for an actual solution, a real treatment.
This can represent one of the best avenues for further developments.
The rights on the drug are actually owned by the biotech company Genkyotex.
The initial development has been carried by researchers at the Monash University.
The human trials, led by Professor Mark Cooper are currently taking place in Australia.
"three things happen In the diabetic kidney" Said Professor Cooper to the Australian media
"it gets inflamed, it scars, and it leaks the protein albumin,".
"We have already shown that this drug stops the inflammation, stops protein leaking, and
stops the scarring.
In particular it is the scarring that causes kidney failure"
The test subjects will be checked for albumin in the urine before and after the 12 months
trial.
They will be administered either this innovative NOX-inhibitor drug or a placebo.
"People will now be able to avoid kidney dialysis, suffer less blindness, avoid heart attacks"
added Professor Cooper.
This study is taking place at 14 facilities across Australia and will last 12 months.
Results will be conclusive in 2020.
I'm keeping my fingers crossed.
Subscribe to this channel and turn on notifications to stay updated.
This is all for today!
If you liked this video, please like and leave a comment!
Thank you for watching!